https://sch58261antagonist.com..../portuguese-comprehe
Poisoning of ipilimumab and nivolumab has also been examined. Outcomes Forty-five patients with metastatic RCC had been included. All patients (100%) received prior ICIs focusing on the PD-1 path. The median age ended up being 62 many years (range, 21-82 years). At a median followup of 12 months, the objective response rate to ipilimumab and nivolumab ended up being 20%. The median progression-free survival while on ipilimumab and nivolumab was 4 months (range, 0.8-19 mo
Like
Comment
Share
